CTNM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
21.0M
+20.3%
17.4M
+3.1%
16.9M
-1.2%
17.1M
+14.6%
14.9M
R&D
16.0M
+25.8%
12.7M
+9.0%
11.6M
-8.7%
12.8M
+16.0%
11.0M
SG&A
5.0M
+5.4%
4.7M
-10.1%
5.3M
+20.6%
4.4M
+10.7%
3.9M
Operating Income
-20966000
-20.3%
-17428000
-3.1%
-16904000
+1.2%
-17115000
-14.6%
-14932000
EBITDA
-20885000
-20.8%
-17294000
-2.8%
-16821000
+1.2%
-17030000
-14.7%
-14851000
Net Income
-18697000
-23.4%
-15154000
-4.8%
-14456000
+4.6%
-15156000
-18.5%
-12792000
EPS (Basic)
$-0.49
-22.5%
$-0.40
-2.6%
$-0.39
+20.4%
$-0.49
-8.9%
$-0.45
EPS (Diluted)
$-0.49
-22.5%
$-0.40
-2.6%
$-0.39
+20.4%
$-0.49
-8.9%
$-0.45
Shares (Diluted)
38.4M
+2.5%
37.5M
+0.3%
37.3M
+20.7%
30.9M
+10.0%
28.1M
Contineum Therapeutics (CTNM) — Financials